Insilico nominates ISM9077 candidate

Insilico Medicine said on August 5 that it had nominated ISM9077 as a preclinical candidate, adding another program to the company’s AI-driven drug discovery pipeline. The Cambridge, Massachusetts-based company described the molecule as a potential first-in-class inhibitor of an undisclosed “Target Y” and said it is being positioned first for ocular diseases including dry age-related macular degeneration, uveitis and dry eye disease. (prnewswire.com) The announcement was framed by Insilico as a platform milestone as much as a single-asset update. Alex Zhavoronkov, the company’s founder, chief executive and chief business officer, said ISM9077 was the company’s 32nd preclinical candidate nomination since 2021 and cited that tally as evidence that generative AI can produce candidates at scale. (prnewswire.com) ### What exactly did Insilico nominate? ISM9077 was nominated as a preclinical candidate, or PCC, which means the program has been advanced into formal preclinical work but has not yet entered human testing. Insilico said the compound is an AI-designed inhibitor of “Target Y,” without publicly naming the target in the release. The August 5 statement said the company sees the first use in eye disease, naming dry AMD, uveitis and dry eye disease. (prnewswire.com) Insilico also said the same mechanism could have relevance in inflammatory disorders and aging-related indications. ### Why is the company calling it a “pipeline-in-a-drug”? Insilico used the phrase “pipeline-in-a-drug” to describe a single mechanism that it believes could support multiple disease programs. (prnewswire.com) In the release, the company said ISM9077 is a “dual-purpose” candidate spanning ocular diseases, inflammatory disorders and aging. That wording points to portfolio breadth rather than near-term regulatory progress. The release did not disclose clinical timelines, efficacy data in humans or a filing date for an investigational new drug application. (prnewswire.com) ### What details did Zhavoronkov give about the molecule? Alex Zhavoronkov said in the release that the candidate combines “a moderately novel target,” “a novel molecule designed from scratch,” and “a novel formulation possibility of eye drop.” He said those features made ISM9077 an example of how generative AI can be used across target selection, molecule design and formulation planning. (prnewswire.com) The eye-drop point is notable because Insilico identified ophthalmology as the lead setting for the program. The company did not provide additional formulation data, dosing details or animal-study results in the announcement. (prnewswire.com) ### How does this fit into Insilico’s broader pipeline? Insilico’s company news page lists the ISM9077 announcement on August 5 and shows a series of earlier pipeline updates, including other AI-discovered candidates and development milestones. (prnewswire.com) A separate May 2026 company release said rentosertib inhalation solution became the 13th program from its pipeline to receive IND clearance, giving Insilico a more advanced set of assets beyond newly nominated preclinical candidates. The company’s count of 32 preclinical candidate nominations since 2021 gives investors and partners one measure of output. Regulatory clearances and human trial starts remain the next harder checkpoints for any individual asset. (prnewswire.com) ### What comes next for ISM9077? The next step for ISM9077 is preclinical development, based on Insilico’s description of the asset as a newly nominated PCC. The August 5 release did not name a trial start date, a partner, or a financing tied specifically to the program. (prnewswire.com) Insilico said more information about the nomination is available through its August 5 release and its corporate news page, where subsequent updates on preclinical studies or any IND-related filing would be expected to appear. (prnewswire.com) (insilico.com)